Document:

Exhibit 10.10

 

Confidential portions of this document have been redacted and
omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC")
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with
the notation “*” and have been filed separately with the SEC.

  

Enumeral Biomedical Holdings, Inc.

 

Non-Qualified Stock Option Agreement

 

Wael Fayad

c/o Enumeral Biomedical Holdings, Inc.

200 CambridgePark Drive, Suite 2000

Cambridge, MA 02140

 

On September 21, 2016, the Board of Directors
(the “Board") of Enumeral Biomedical Holdings, Inc. (the “Company”) approved a grant (the “Grant”)
of a Non-Qualified Stock Option (the “Option”) to you to purchase common stock, $0.01 par value per share, of the Company
(the “Common Stock”). The Option shall constitute and be treated at all times by you and the Company as a “non-qualified
stock option” for Federal income tax purposes and shall not constitute and shall not be treated as an “incentive stock
option” as defined under Section 422(b) of the Internal Revenue Code of 1986, as amended.

 

You are granted an Option to purchase 1,750,000
shares of Common Stock at the price of $0.19 per share which represents the Fair Market Value (as defined in the Company’s
2014 Equity Incentive Plan, as amended (the “Plan”)) of the Common Stock on the date of grant. This Grant is made as
a matter of separate inducement and not in lieu of any salary or other compensation for your services. The date of grant of this
Option is September 21, 2016.

 

		1.	Vesting. This Option may be exercised only to the extent it is vested. For purposes of this
section, reference is hereby made to that certain Incentive Stock Option Agreement, dated as of September 21, 2016, between the
Company and Wael Fayad, granting 750,000 options to purchase shares of Common Stock, which shall vest and become exercisable upon
the achievement of the performance criteria set forth therein (the “Tranche A Options”).

 

Subject to you remaining employed
by the Company or in the service of the Company on its Board of Directors on the applicable vesting dates below, this Option shall
vest as follows:

 

     

     

    

  

		·	750,000 shares underlying this Option shall vest and become exercisable
upon the Company entering into a second (i.e., in addition to the transaction described in the Tranche A Options agreement) collaboration
and/or licensing agreement with a corporate partner on terms acceptable to the Board that provides the Company will receive at
least $* in upfront fees upon signing (the “Tranche B Options”); provided that, in the event that the Company enters
into collaboration and/or licensing agreement(s) with one or more corporate partners on terms acceptable to the Board that collectively
provide the Company will receive at least an aggregate of $* in upfront fees upon signing, all of the Tranche A Options and Tranche
B Options shall vest and become exercisable; and

 

		·	1,000,000 shares underlying this Option shall vest and become exercisable upon the closing of an
equity financing transaction on terms acceptable to the Board with gross proceeds to the Company of at least $*, which may include
proceeds from the exercise of some or all of the warrants issued in connection with the Company’s July 2014 private placement
offering (the “Tranche C Options”); provided that, in the event the Company raises at least $* in one or more transactions
(including proceeds from the exercise of some or all of the warrants issued in connection with the Company’s July 2014 private
placement offering), with at least $* raised through non-dilutive collaboration and/or licensing agreements, all of the Tranche
A Options, Tranche B Options, and Tranche C Options shall vest and become exercisable.

 

		2.	Duration of Option. Except as otherwise provided herein, this option may be exercised for
three (3) months after you cease serving as an employee of the Company or a member of the Company’s Board of Directors, provided,
however in the event your termination of service is due to your death or disability, the Option may be exercised for one year following
such event. In no case, however, may the Option be exercised after September 20, 2026.

 

		3.	Exercise of Option.

 

		(a)	Right to Exercise. This Option is exercisable during its term in accordance with the Vesting Schedule
set out in Section 1.

 

		(b)	Method of Exercise. This Option is exercisable by delivery of an exercise notice, in the form attached
as Exhibit A (the "Exercise Notice"), which shall state the election to exercise the Option, the number of shares of
Common Stock in respect of which the Option is being exercised (the "Exercised Shares"), and such other representations
and agreements as may be required by the Company. The Exercise Notice shall be completed by you and delivered to the Corporate
Secretary. The Exercise Notice shall be accompanied by payment of the aggregate exercise price as to all Exercised Shares. This
Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by such aggregate
exercise price.

 

No shares of Common Stock shall be issued
pursuant to the exercise of this Option unless such issuance and exercise comply with applicable laws. Assuming such compliance,
for income tax purposes the Exercised Shares shall be considered transferred to you on the date the Option is exercised with respect
to such Exercised Shares.

 

     

     

    

  

		4.	Method of Payment. Payment of the aggregate Exercise Price shall be by any of the following,
or a combination thereof, at your election:

 

		(a)	cash;

 

		(b)	check;

 

		(c)	consideration received by the Company under a cashless exercise program implemented by the Company;
or

 

		(d)	surrender of other shares of Common Stock which (i) in the case of shares of Common Stock acquired
upon exercise of an option, have been owned by you for more than six (6) months on the date of surrender, and (ii) have a fair
market value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares.

 

		5.	Non-Assignability of Option. This Option may not be transferred in any manner otherwise
than by will or by the laws of descent or distribution and may be exercised during your lifetime only by you except in the case
of your disability, this Option may be exercised by your representative. The terms of this Agreement shall be binding upon your
executors, administrators, heirs, successors and assigns.

 

		6.	Incorporation of Provisions of the Plan. You acknowledge and agree that while this Grant
is not made pursuant to the Plan, it is the intention of the Company for you to have all of the benefits and advantages of the
Plan. Accordingly, the terms and conditions of the Plan are incorporated by reference into this Grant as if they had been stated
herein with such the necessary modifications to the terms and conditions of the Plan that are being incorporated by reference to
avoid inconsistencies between the Grant and the Plan; it being understood that in the event or a direct conflict or contradiction
between a term or condition of the Grant and the Plan, the term or condition of the Grant shall control.

 

		7.	Covenants. You hereby covenant and agree with the Company that if, at the time of exercise
of the Option, there does not exist a Registration Statement on an appropriate form under the Securities Act of 1933, as amended
(the “Act”), which Registration Statement shall have become effective and shall include a prospectus which is current
with respect to the shares subject to the Option, you shall make the representations (i) that you are purchasing the shares for
your own account and not with a view to the resale or distribution thereof, (ii) that any subsequent offer for sale or sale of
any such shares shall be made either pursuant to (x) a Registration Statement on an appropriate form under the Act, which Registration
Statement shall become effective and shall be current with respect to the shares being offered and sold, or (y) a specific exemption
from the registration requirements of the Act, but in claiming such exemption, you shall, prior to any offer for sale or sale of
such shares, obtain a favorable written opinion from counsel for or approved by the Company as to the applicability of such exemption
and (iii) that you agree that the certificates evidencing such shares shall bear a legend to the effect of the foregoing.

 

     

     

    

  

This Agreement and the provisions of the
Plan, as incorporated by reference in this Agreement, constitute the entire agreement of the parties with respect to the subject
matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and you with respect to the
subject matter hereof, and may not be modified adversely to your interest except by means of a writing signed by the Company and
you. This Agreement is governed by the laws of the State of Delaware.

 

This Agreement is not a contract of employment
and the terms of your employment shall not be affected hereby or by any agreement referred to herein except to the extent specifically
so provided herein or therein. Nothing herein shall be construed to impose any obligation on the Company to continue your employment,
and it shall not impose any obligation on your part to remain in the employ of the Company thereof.

 

By your acceptance hereof, you agree to
reimburse the Company for any taxes required by any government to be withheld or otherwise deducted and paid by the Company in
respect of the Grant. In lieu thereof, the Company shall have the right to withhold the amount of such taxes from any other sums
due or to become due from the Company to you.

 

By your signature and the signature of the Company's representative
below, you and the Company agree that the Option is granted under and governed by the terms and conditions of this Agreement and
the provisions of the Plan, as incorporated by reference in this Agreement. You have reviewed the Plan and this Agreement in their
entirety, have had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understand all provisions
of the Plan and this Agreement. You hereby agree to accept as binding, conclusive and final all decisions or interpretations of
the Board of Directors upon any questions relating to the Plan and Agreement. You further agree to notify the Company upon any
change in your residence address indicated below.

 

	OPTIONEE	 	ENUMERAL BIOMEDICAL HOLDINGS, INC.
	 	 	 
	/s/ Wael Fayad	 	/s/ Kevin G. Sarney
	 	 	 	 
	Signature	 	By:	Kevin G. Sarney
	 	 	 	 
	 	 	Title:	Vice President of Finance, Chief Accounting Officer and Treasurer

 

	Wael Fayad	 
	Print Name	 

 

Address:

c/o Enumeral Biomedical Holdings, Inc.

200 CambridgePark Drive, Suite 2000

Cambridge, MA 02140

 

     

     

    

 

Exhibit A

 

EXERCISE NOTICE

 

Enumeral Biomedical Holdings, Inc.

200 CambridgePark Drive, Suite 2000

Cambridge, MA 02140

 

 

 

 (date)

 

Re: Non-Qualified Stock Option

 

Notice is hereby given pursuant to Section
3 of my Agreement that I elect to purchase the number of shares set forth below at the exercise price set forth in my Agreement:

 

	 	Stock Option dated:	 	 
	 	 	 	 
	 	Number of shares being purchased:	 	 
	 	 	 	 
	 	Option Exercise Price Per Share	 	 
	 	 	 	 
	 	Aggregate Option Exercise Price	 	 

 

A check in the amount of the aggregate
price of the shares being purchased is attached.

 

I understand that the shares of Common
Stock that I receive upon exercise of my Option may not be freely tradable.

 

Further, I understand that, as a result
of this exercise of rights, I will recognize income in an amount equal to the amount by which the fair market value of the shares
of Common Stock exceeds the exercise price. I agree to report such income in accordance with then applicable law and to cooperate
with the Company in establishing the withholding and corresponding deduction to the Company for its income tax purposes.

 

I agree to provide to the Company such
additional documents or information as may be requested by the Company or required by law.

 

	 	 
	(Signature)	 
	 	 
	 	 
	(Name of Optionee)Exhibit 10.11

 

 

Confidential
portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities
and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The
redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. AMENDMENT
OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE Page of Pages 1 | 4 2, AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE
4. REQUISITION/PURCHASE REO.NO. 5 PROJECT NO {If applicable) 0004 09/15/2016 6 ISSUED BY CODE IO-NCI 7. ADMINISTERED BY (If other
than Item 6) CODE ADM-NCI National Institutes of Health National Institutes of Health National Cancer Institute National Cancer
Institute Bethesda, MD 20892-7 511 Bethesda, MD 20892-7511 B. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP
Code) ENUMERAL BIOMEDICAL CORP.:1217635 (x) 9A. AMENDMENT OF SOLICITATION NO 200 CAMBRIDGEPARK DRIVE 2000 98. DATED (SEE ITEM
11) CAMBRIDGE, MA 021402307 10A. MODIFICATION OF CONTRACT/ORDER NO. X HHSN261201400048C 10B.DATED (SEE ITEM 13) CODE FACILITY
CODE 09/10/2014 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS | | The above numbered solicitation is amended as set
forth in Item 14. The hour and dale specified for receipt of Offers | |is extended. | | is not extended Offers must acknowledge
receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
(a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each
copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment
numbers, FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND
DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted
, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this
amendment, and is received prior to the opening hour and dale specified. 12. ACCOUNTING AND APPROPRIATION DATA (If required) See
Schedule 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM
14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE
CONTRACT ORDER NO.IN ITEM 10A. • B.THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such
as changes in paying office, appropriation date, etc) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS
SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OP. x FAR 43.103 (a)(3) and by mutual agreement D. OTHER {Specify
type of modification and authority) E. IMPORTANT: Contractor | |is not. IXl is required to sign this document and return 1 copies
to the issuing office 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract
subject matter where feasible.) SBIR Phase II Topic 309: Deployment of Prototype System for Detection of Multiple Analytes in
Small Tissue Samples. Period of Performance: 9/16/2014 - 3/15/2017 The purpose of Modification 0004 is to extend the Period of
Performance and update the Contract Specialist in Article F.2. Delivery: 09/15/2014 Delivery Location Code: 2115 E JEFFERSON ST
2115 E Jefferson St MSC 8500 Suite 48 432 Bethesda MD 20892-8500 US

 

     

     

    

 

 

Continued...
Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains
unchanged and in full force and effect 15A. NAME AND TITLE OF SIGNER (Type or print) Kevin Sarney, VP of Finance 16A. NAME AND
TITLE OF CONTRACTING OFFICER (Type or print) C. TIMOTHY CRILLEY 15B.CONTRACTOR/OFFEROR /s/ Kevin Sarney •(Signature of person
authorized to sign) 15C. DATE SIGNED 9/13/16 168 UNITED STATES OF AMERICA /s/ C. Timothy Crilley (Signature of Contracting Officer)
16C DATE SIGNED 9/13/16 NSN 7540-01-152-8070 Previous edition unusable STANDARD FORM 30 (REV. 10-<33) Prescribed by GSA FAR
(48 CFR) 53 243

 

     

     

    

 

 

REFERENCE
NO. OF DOCUMENT BEING CONTINUED CONTINUATION SHEET HHSN261201400048C/0004 NAME OF OFFEROR OR CONTRACTOR ENUMERAL BIOMEDICAL CORP.:1217635
ITEM NO. (A) SUPPLIES/SERVICES (B) QUANTITY (C) UNIT (D) UNIT PRICE (E) AMOUNT (F)

 

     

     

    

  

 

1 Payment:
Approved By, NCI Branch C Invoices Paid By: NIH Commercial Accounts Br 2115 East Jefferson St, MSC 8500 Room 4B-432 Bethesda,
MD 20892-8500 FOB: Destination Period of Performance: 09/16/2014 to 03/15/2017 Change Item 1 to read as follows(amount shown is
the obligated amount): Special Handling: None HHSN261201400048C; Topic 309 Development of Low Cost Small Sample Multi-Analytes
Tech for Cancer Diagnosis, Prognosis & Early Detection Title: Deployment of Prototype System for Detection of Multi. Anal.
in Small Tissue Sample Period of Performance 9/15/2014 - 3/15/2017 Obligated Amount: $0.00 Delivery To: 9609/1W550 Product/Service
Code: ANll Product/Service Description: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH) Project Data: 125132.l.HNC1J NCI OD SBIR(DC
SMALL BUSINESS INNOVATION RESEARCH (SB.2555 RESEARCH AND DEVELOPMENT.09/02/2014 Accounting Info: 08024920141DA0.2014.03.Cl00.HNC1000000C.E.00014.40
6.SBIR.2555.610001.9999.9999.9999 Funded: $0.00 0.00 NSN 7540-01-152-6067 OPTIONAL FORM 336 (4- 66) Sponsored by GSA FAR C46 CFRl
53110

 

     

     

    

 

 

1. The
purpose of this Modification, 0004, is to update Articles 8.3 "Advance Understandings", F.1 "Period of Performance"
and F.2 "Deliveries". 2. ARTICLE 8.3.b "Advance Understandings is update to reflect the extension of the subcontractor
periods of performance FROM: b. Subcontract A cost-reimbursement type subcontract with Memorial Sloan Kettering Cancer Center
(MSKCC) for the installation and work with the prototype system and optimization of the process from the standpoint of end-users
for an amount not to exceed $* for the period 9/16/14-9/15/16. A copy of the signed, executed subcontract shall be provided to
the Contracting Officer prior to performing work under this contract. A cost-reimbursement type subcontract with the Ragon Institute
for their participation in the evaluation of the prototype for an amount not to exceed $* for the period 9/16/14-9/15/16. A copy
of the signed, executed subcontract shall be provided to the Contracting Officer prior to performing work under this contract.
A cost-reimbursement type subcontract with Memorial Sloan Kettering Cancer Center (MSKCC) for the installation and work with the
prototype system and optimization of the process from the standpoint of end-users for an amount not to exceed $* for the period
9/16/14-03/15/2017. A copy of the signed, executed subcontract shall be provided to the Contracting Officer prior to performing
work under this contract. A cost-reimbursement type subcontract with the Ragon Institute for their participation in the evaluation
of the prototype for an amount not to exceed $* for the period 9/16/14- 03/15/2017. A copy of the signed, executed subcontract
shall be provided to the Contracting Officer prior to performing work under this contract. 3. ARTICLE F.1"Deliveries"-
is updated to reflect a no cost Period of Performance extension. The period of performance is updated from 9/16/2014-9/15/2016
to 9/16/2014-3/15/2017. 4. Article F.2.b "Deliveries is updated as shown below: FROM: b. The above items shall be addressed
and emailed to ncibranchcinvoices@mail.nih. gov . The following addresses are provided for general correspondence and other deliveries:
Addressee Deliverable Item No. Quantity Mandie S. White , Contracting Officer National Cancer Institute 1-17 One (1) electronic
copy *

 

 

 

    2 

     

    

  

 

Office
of Acquisitions, Room 4036 Riverside Five, Suite 400 8490 Progress Drive Frederick, MD 21701 *, COR National Cancer Institute
NCI SBIR & STTR Programs , Room 9609 Medical Center Drive, MSC 9705 Bethesda, MD 20892-9705 1-9 One (1) electronic copy ncibranchcinvoices@mail.nih.gov

OPERA,
OEH, NIH 6705 Rockledge Drive Suite 310, MSC 7980 Bethesda , Maryland 20892-7980 12 One (1) hard copy to OPERA; One (1) electronic
copy ncibranchcinvoices@mail.nih.gov

b.
The above items shall be addressed and emailed to ncibranchcinvoices@mail.nih .gov. The following addresses are provided for general
correspondence and other deliveries: Addressee Deliverable Item No. Quantity *, Contract Specialist National Cancer Institute
Office of Acquisitions, Room 4036 Riverside Five, Suite 400 8490 Progress Drive Frederick, MD 21701 1-17 One (1) electronic copy
* *, COR National Cancer Institute NCI SBIR & STTR Programs, Room 9609 Medical Center Drive, MSC 9705 Bethesda, MD 20892-9705
1-9 One (1) electronic copy ncibranchcinvoices@mail.nih.gov

OPERA,
OEH, NIH 6705 Rockledge Drive Suite 310, MSC 7980 Bethesda , Maryland 20892-7980 12 One (1) hard copy to OPERA; One (1) electronic
copy ncibranchcinvoices@mail.nih.gov

5.
All other terms and conditions remain unchanged and are in full force and effect.

 

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]